Aaron Bonner-Jackson
Overview
Explore the profile of Aaron Bonner-Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hurley R, Lapin B, Jones S, Crawford A, Leverenz J, Bonner-Jackson A, et al.
Front Neurol
. 2024 May;
15:1374827.
PMID: 38742046
In addition to Alzheimer's disease (AD), the hippocampus is now known to be affected in variants of frontotemporal degeneration (FTD). In semantic variant primary progressive aphasia (svPPA), characterized by language...
2.
Bonner-Jackson A, Vangal R, Li Y, Thompson N, Chakrabarti S, Krishnan K
Am J Med
. 2024 Feb;
138(2):337-345.
PMID: 38331138
Objective: Quantify cognitive deficits in patients with postacute sequelae of COVID-19 (PASC) and identify key variables related to cognitive impairment in PASC. Method: Patients with polymerase chain reaction-confirmed COVID-19 underwent...
3.
Krishnan K, Miller A, Reiter K, Bonner-Jackson A
Arch Clin Neuropsychol
. 2022 Feb;
37(4):729-737.
PMID: 35136912
Objective: A subset of individuals with coronavirus disease 2019 (COVID-19) appears to develop persisting cognitive and medical symptoms. Research in the acute stages of illness, generally utilizing cognitive screening measures...
4.
Pillai J, Bena J, Bonner-Jackson A, Leverenz J
Alzheimers Res Ther
. 2021 Jan;
13(1):31.
PMID: 33485373
Background: APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer's pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive...
5.
Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease
Pillai J, Bena J, Bebek G, Bekris L, Bonner-Jackson A, Kou L, et al.
Ann Clin Transl Neurol
. 2020 Jul;
7(7):1225-1239.
PMID: 32634865
Objective: To determine the inflammatory analytes that predict clinical progression and evaluate their performance against biomarkers of neurodegeneration. Methods: A longitudinal study of MCI-AD patients in a Discovery cohort over...
6.
Pillai J, Bonner-Jackson A, Bekris L, Safar J, Bena J, Leverenz J
J Alzheimers Dis
. 2019 Jul;
70(4):1051-1058.
PMID: 31306137
Background: Cerebrospinal fluid (CSF) levels of total tau (t-tau) protein are thought to reflect the intensity of the neuronal damage in neurodegeneration, including Alzheimer's disease (AD). The recent link of...
7.
Pillai J, Bonner-Jackson A, Floden D, Fernandez H, Leverenz J
Mov Disord Clin Pract
. 2018 Oct;
5(3):283-289.
PMID: 30363404
Background: How accurate are mild cognitive impairment (MCI) patients in assessing their cognitive and functional deficit is often unclear to the clinician. The accuracy of patient self-appraisal in Parkinson's disease-MCI...
8.
Uchida A, Pillai J, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, et al.
Invest Ophthalmol Vis Sci
. 2018 Jun;
59(7):2768-2777.
PMID: 29860463
Purpose: To investigate outer retinal parameters among patients with various chronic neurodegenerative disorders by using spectral-domain coherence tomography (OCT) in a prospective cross-sectional cohort study. Methods: A total of 132...
9.
Pillai J, Butler R, Bonner-Jackson A, Leverenz J
Dement Geriatr Cogn Disord
. 2016 Sep;
42(1-2):106-16.
PMID: 27623397
Aims: We examined the effect of vascular or Lewy body co-pathologies in subjects with autopsy-confirmed Alzheimer's disease (AD) on the rate of cognitive and functional decline and transition to dementia....
10.
Harrington D, Long J, Durgerian S, Mourany L, Koenig K, Bonner-Jackson A, et al.
Mov Disord
. 2016 Sep;
31(11):1664-1675.
PMID: 27620011
Objectives: Diffusivity in white-matter tracts is abnormal throughout the brain in cross-sectional studies of prodromal Huntington's disease. To date, longitudinal changes have not been observed. The present study investigated cross-sectional...